In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Bristol-Myers Squibb's current price at $63.63 is significantly below its PERT-weighted fair value of $143.82, indicating substantial upside potential supported by strong DCF and growth scores. Low leverage but moderate liquidity suggests manageable financial risk, while the Monte Carlo model shows high volatility but zero downside below current price. This valuation spread signals opportunities amid inherent market uncertainty.